Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Acumen Pharmaceuticals, Inc. amended Sales Agreement with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, BTIG, LLC valued at aggregate offering price of up to $50,000,000 (effective 2023-04-27).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, BTIG, LLC
- Value
- aggregate offering price of up to $50,000,000
- Effective
- 2023-04-27
Exact text from the filing
On April 27, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an amendment (“Amendment No. 1”) to the Sales Agreement, dated as of July 1, 2022 (the “Sales Agreement” and, as amended by Amendment No. 1, the “Amended Sales Agreement”) with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated and BTIG, LLC (collectively referred to as “Sales Agents” and each individually a “Sales Agent”), pursuant to which the Company may sell its common stock, par value $0.0001 per share, from time to time through the Sales Agents in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1934, as amended (the “Securities Act”).
View on SEC.gov